BMO Capital raised the firm’s price target on Terns Pharmaceuticals (TERN) to $22 from $15 and keeps an Outperform rating on the shares. Even following its results, shares may be undervalued with products like Novartis’s Scemblix estimated to reach well over $3B in peak sales, the analyst tells investors in a research note. Investor attention now turns to ASH full data and incremental updates in 2026 regarding Phase 3 trial design with FDA, the firm added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright
- H.C. Wainwright upgrades Terns on ‘compelling’ TERN-701 data
- Terns Pharmaceuticals price target raised to $27 from $14 at Barclays
- Terns Pharmaceuticals price target raised to $22 from $15 at BMO Capital
- Terns Pharmaceuticals price target raised to $35 from $28 at Jefferies